{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T19:04:09Z","timestamp":1773342249651,"version":"3.50.1"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:00:00Z","timestamp":1770336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:00:00Z","timestamp":1770336000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s00228-026-04003-z","type":"journal-article","created":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T07:12:58Z","timestamp":1770361978000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The phenprocoumon echo: Elevated INR risk after VKA reversal \u2013 A retrospective analysis of phenprocoumon and acenocoumarol in clinical practice in a Dutch teaching hospital"],"prefix":"10.1007","volume":"82","author":[{"given":"Emma M.C.","family":"Tijmensen-Reijers","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soha","family":"Saleh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anita","family":"Griffioen-Keijzer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renate C.A.E.","family":"van Uden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Folkert","family":"Brijker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melchior C.","family":"Nierman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthijs L.","family":"Becker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,6]]},"reference":[{"key":"4003_CR1","doi-asserted-by":"crossref","unstructured":"Bayer V, Kotalczyk A, Kea B, Teutsch C, Larsen P, Button D et al (2022) Global oral anticoagulation use varies by region in patients with recent diagnosis of atrial fibrillation: the GLORIA-AF phase III registry. J Am Heart Assoc. ;11(6)","DOI":"10.1161\/JAHA.121.023907"},{"issue":"4","key":"4003_CR2","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1161\/CIRCULATIONAHA.121.056355","volume":"145","author":"AP Carnicelli","year":"2022","unstructured":"Carnicelli AP, Hong H, Connolly SJ, Eikelboom J, Giugliano RP, Morrow DA et al (2022) Direct oral anticoagulants versus warfarin in patients with atrial fibrillation: Patient-Level network Meta-Analyses of randomized clinical trials with interaction testing by age and sex. Circulation 145(4):242\u2013255","journal-title":"Circulation"},{"issue":"1","key":"4003_CR3","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJM199507063330103","volume":"333","author":"S Cannegieter","year":"1995","unstructured":"Cannegieter S, Rosendaal F, Wintzen A, Van Der Meer F, Vandenbroucke J, Bri\u00ebt E (1995) Optimal oral anticoagulant therapy in patients with mechanical heart valves. N Engl J Med 333(1):11\u201317","journal-title":"N Engl J Med"},{"issue":"4","key":"4003_CR4","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1093\/eurheartj\/ehz405","volume":"41","author":"SV Konstantinides","year":"2020","unstructured":"Konstantinides SV, Meyer G, Bueno H, Gali\u00e9 N, Gibbs JSR, Ageno W et al (2020) 2019 ESC guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European respiratory society (ERS). Eur Heart J 41(4):543\u2013603","journal-title":"Eur Heart J"},{"issue":"5","key":"4003_CR5","doi-asserted-by":"publisher","first-page":"E1","DOI":"10.1093\/ejcts\/ezw313","volume":"50","author":"P Kirchhof","year":"2016","unstructured":"Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B et al (2016) 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur J Cardiothorac Surg 50(5):E1\u201388","journal-title":"Eur J Cardiothorac Surg"},{"key":"4003_CR6","unstructured":"Nederlandse Vereniging van Internisten Dutch guideline antithrombotic therapy (Antitrombotisch beleid, beleid bloedingen of ingreep bij VKA) [Internet]. 2021 [cited 2025 Mar 13]. Available from: https:\/\/richtlijnendatabase.nl\/richtlijn\/antitrombotisch_beleid\/strategie_bloeding_ingreep_bij_antistolling\/beleid_bloedingen_of_ingreep_bij_vka.html"},{"issue":"1","key":"4003_CR7","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1055\/s-0038-1650514","volume":"76","author":"FJ van der Meer","year":"1996","unstructured":"van der Meer FJ, Rosendaal FR, Vandenbroucke JP, Bri\u00ebt E (1996) Assessment of a bleeding risk index in two cohorts of patients treated with oral anticoagulants. Thromb Haemost 76(1):12\u20136","journal-title":"Thromb Haemost"},{"issue":"5","key":"4003_CR8","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/j.jacc.2020.04.053","volume":"76","author":"GF Tomaselli","year":"2020","unstructured":"Tomaselli GF, Mahaffey KW, Cuker A, Dobesh PP, Doherty JU, Eikelboom JW et al (2020) 2020 ACC expert consensus decision pathway on management of bleeding in patients on oral anticoagulants: A report of the American college of cardiology solution set oversight committee. J Am Coll Cardiol 76(5):594\u2013622","journal-title":"J Am Coll Cardiol"},{"key":"4003_CR9","unstructured":"Prothya Biosolutions BV, Cofact 250 IU & 500IU \u2013 Summary of Product Characteristics [Internet]. 2022 [cited 2025 Aug 5]. Available from: https:\/\/www.geneesmiddeleninformatiebank.nl\/smpc\/h17060_smpc.pdf"},{"key":"4003_CR10","unstructured":"Aurobindo BV Acenocoumarol 1\u00a0mg tablets - Summary of Product Characteristics [Internet]. 2025 [cited 2025 Aug 5]. Available from: https:\/\/www.geneesmiddeleninformatiebank.nl\/smpc\/h128376_smpc.pdf"},{"key":"4003_CR11","unstructured":"Sandoz BV Fenprocoumon Sandoz 3\u00a0mg, tablets \u2013 Summary of Product Characteristics [Internet]. 2024 [cited 2025 Aug 5]. Available from: https:\/\/www.geneesmiddeleninformatiebank.nl\/smpc\/h21068_smpc.pdf"},{"key":"4003_CR12","unstructured":"Teva UKL Warfarin 1\u00a0mg, tablets - Summary of Product Characteristics [Internet]. 2023 [cited 2025 Aug 5]. Available from: https:\/\/products.tevauk.com\/mediafile\/id\/53444.pdf"},{"issue":"12","key":"4003_CR13","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.2165\/00003088-200544120-00003","volume":"44","author":"M Ufer","year":"2005","unstructured":"Ufer M (2005) Comparative pharmacokinetics of vitamin K antagonists warfarin, phenprocoumon and acenocoumarol. Clin Pharmacokinet 44(12):1227\u20131246","journal-title":"Clin Pharmacokinet"},{"key":"4003_CR14","doi-asserted-by":"crossref","unstructured":"Lindhoff-Last E, Birschmann I, Bidenharn AJ, Kuhn J, Lindau S, Konstantinides S et al (2022) Pharmacokinetics of phenprocoumon in emergency Situations\u2013Results of the prospective observational RADOA-Registry (Reversal agent use in patients treated with direct oral anticoagulants or vitamin K antagonists Registry). Pharmaceuticals. ;15(11)","DOI":"10.3390\/ph15111437"},{"key":"4003_CR15","doi-asserted-by":"crossref","unstructured":"Desmettre T, Dehours E, Samama CM, Jhundoo S, Pujeau F, Guillaudin C et al (2012) Reversal of Vitamin K Antagonist (VKA) effect in patients with severe bleeding: a French multicenter observational study (Optiplex) assessing the use of Prothrombin Complex Concentrate (PCC) in current clinical practice. Crit Care. ;16(5)","DOI":"10.1186\/cc11669"},{"issue":"2","key":"4003_CR16","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1046\/j.1365-2141.1999.01196.x","volume":"104","author":"FJA van Penning- Beest","year":"1999","unstructured":"van Penning- Beest FJA, Rosendaal FR, Grobbee DE, Van Meegen E, Stricker BHC (1999) Course of the international normalized ratio in response to oral vitamin K1 in patients overanticoagulated with phenprocoumon. Br J Haematol 104(2):241\u20135","journal-title":"Br J Haematol"},{"issue":"36","key":"4003_CR17","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.jcrc.2016.06.024","volume":"36","author":"JH Sin","year":"2016","unstructured":"Sin JH, Berger K, Lesch CA (2016) Four-factor prothrombin complex concentrate for life-threatening bleeds or emergent surgery: A retrospective evaluation. J Crit Care 36(36):166\u2013172","journal-title":"J Crit Care"},{"key":"4003_CR18","unstructured":"Van Miert JHA, Piersma-Wichers M, Meijer K Overstappen van acenocoumarol naar fenprocoumon Stap richting gepersonaliseerde antistolling?"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-026-04003-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-026-04003-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-026-04003-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T09:53:55Z","timestamp":1773309235000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-026-04003-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,6]]},"references-count":18,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["4003"],"URL":"https:\/\/doi.org\/10.1007\/s00228-026-04003-z","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,6]]},"assertion":[{"value":"25 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"74"}}